Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi
| Autor: | Cristina Tecchio, Lucia Morello, Carlo Visco, Chiara De Philippis, Roberta Sciarra, Maria Chiara Tisi, Maria Isabel Alvarez De Celis, Luca Nassi, Irene Dogliotti, Alice Di Rocco, Luigi Marcheselli, Nicola Bianchetti, Annalisa Arcari, Vittorio Ruggero Zilioli, Michele Merli, Anna Lia Molinari, Guido Gini, Tommasina Perrone, Annalisa Chiappella, Valentina Bozzoli, Stefano Volpetti, Francesca Maria Quaglia, Stefan Hohaus, Matteo Pelosini, Alberto Fabbri, Daniele Vallisa |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Adult Homologous Cancer Research medicine.medical_specialty Transplantation Conditioning Lymphoma Lymphoma Mantle-Cell chemistry.chemical_compound Refractory immune system diseases allogeneic stem cell transplantation ibrutinib hemic and lymphatic diseases Internal medicine medicine Humans Transplantation Homologous Retrospective Studies Transplantation Mantle cell lymphoma business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged Mantle-Cell medicine.disease Chimeric antigen receptor Neoplasm Recurrence chemistry Local Ibrutinib Cytarabine Rituximab Stem cell Neoplasm Recurrence Local business medicine.drug Stem Cell Transplantation |
| Popis: | The role of allogeneic stem cell transplantation (allo-SCT) in mantle cell lymphoma (MCL) is uncertain, even more in the era of bruton's tyrosine kinase inhibitors (BTKi) and chimeric antigen receptor T-cells. We retrospectively analyzed 55 patients who underwent allo-SCT for MCL relapsed or refractory (r/r) after rituximab and high-dose cytarabine within the MANTLE-FIRST project. With a median follow-up of 3.7 years, non-relapse mortality (NRM), progression-free survival, and overall survival were 23%, 53%, and 56%, respectively. NRM was significantly higher in the case of acute graft-versus-host disease, > 2 prior lines of therapy, age > 60 years. The outcome was similar for patients with early (≤24 months) and late progression of disease. The use of BTKi as a bridge to allo-SCT did not increase the toxicity and allowed a good control of disease. Our real-life experience confirms that allo-SCT still represents an option in MCL patients, especially if young and early-relapsed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|